LUTATHERA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Poland, Spain.

Active ingredients

The drug LUTATHERA contains one active pharmaceutical ingredient (API):

1	Lutetium ¹⁷⁷Lu oxodotreotide UNII AE221IM3BB - LUTETIUM OXODOTREOTIDE LU-177
	Lutetium (177Lu) oxodotreotide has a high affinity for subtype 2 somatostatin receptors (sst2). It binds to malignant cells which overexpress sst2 receptors. Lutetium-177 (177Lu) is a βemitting radionuclide with a maximum penetration range in tissue of 2.2 mm (mean penetration range of 0.67 mm), which is sufficient to kill targeted tumour cells with a limited effect on neighbouring normal cells.
	Read more about Lutetium ¹⁷⁷Lu oxodotreotide

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LUTATHERA Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)
LUTATHERA Solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
V10XX04		V Various → V10 Therapeutic radiopharmaceuticals → V10X Other therapeutic radiopharmaceuticals → V10XX Various therapeutic radiopharmaceuticals
Discover more medicines within V10XX04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1617184
ES	Centro de información online de medicamentos de la AEMPS	1171226001
FR	Base de données publique des médicaments	60823764
HK	Department of Health Drug Office	66645, 66646
IL	מִשְׂרַד הַבְּרִיאוּת	8801
IT	Agenzia del Farmaco	045677010
JP	医薬品医療機器総合機構	4291458A1020
LT	Valstybinė vaistų kontrolės tarnyba	1084163
PL	Rejestru Produktów Leczniczych	100396207
US	FDA, National Drug Code	69488-003